We recently updated our Privacy Notice and Terms of Use.
Med-IQ
Recent Advances in the Treatment of Hematologic Malignancies
Webcast Webcast

Recent Advances in the Treatment of Hematologic Malignancies



This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ       Duke Medicine

Released:
10/11/18
Expires:
10/10/19
PDF:

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
10/11/18

Expires:
10/10/19

PDF:

Maximum Credits:
0.5
Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
10/11/18
Expires:
10/10/19
PDF:


Maximum Credits:
0.5


Overview: In this 30-minute webcast, expert faculty explore recent advances in the treatment of hematologic malignancies. In particular, CAR T-cell therapy for relapsed and refractory diffuse large B-cell lymphoma and FLT3-targeted treatment in AML are discussed.

CME Information:

Faculty
Harry P. Erba, MD, PhD
Professor of Medicine
Director, Duke Leukemia Program
Duke University School of Medicine
Durham, NC
 
Matthew McKinney, MD
Assistant Professor of Medicine
Duke University School of Medicine
Durham, NC
 
Activity Planners
Julie Blum, PhD
Senior Clinical Content Manager
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Learning Objectives
Upon completion, participants should be able to:

  • Describe recent clinical data supporting the use of novel agents that target FLT3 for the treatment of AML
  • Identify aspects of current and emerging CAR T-cell therapies, including targets, activity, and toxicity

Target Audience
This activity is intended for community oncologists  and community hematologic oncologists.

Statement of Need
The annual American Society of Clinical Oncology (ASCO) meeting showcases cutting-edge research on treatment modalities and new therapies in the field of oncology. It is important for oncologists who manage patients with hematologic malignancies to be aware of data presented at ASCO 2018 on the effectiveness of novel treatment strategies, including CAR T-cell therapy and other novel targeted agents. 

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ      Duke Medicine

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
 
Instructions to Receive Credit
To receive credit, read the introductory CME material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: October 11, 2018
Expiration Date: October 10, 2019
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Harry P. Erba, MD, PhD
Consulting fees/advisory boards: Agios Pharmaceuticals, Celgene Corporation, Daiichi Sankyo, Co., Ltd., GlycoMimetics, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals, MacroGenics, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Seattle Genetics                                         
Fees received for promotional/non-CME activities: Agios Pharmaceuticals, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation                                         
Contracted research: Agios Pharmaceuticals, Amgen, Astellas Pharma US, Inc., Celator Pharmaceuticals, Daiichi Sankyo, Co., Ltd., ImmunoGen, Janssen Pharmaceutics, Inc., Juno Therapeutics, Millennium: the Takeda Oncology Company, Seattle Genetics                                         
Other: Celgene Corporation, Daiichi Sankyo, Co., Ltd., GlycoMimetics, Inc.
 
Matthew McKinney, MD
Consulting fees/advisory boards: Kite Pharma, Seattle Genetics, Spectrum Pharmaceuticals

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information 
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email info@med-iq.com.
                     
System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Copyright
© 2018 Med-IQ, Inc. and Duke University Health System

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.